EVALUATION OF ANTIBODY IMMUNOTHERAPY FOR HCV IN CHIMPANZEES

黑猩猩 HCV 抗体免疫治疗的评估

• 批准号: 8357719
• 负责人: Robert E LANFORD
• 金额: $ 3.66万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357719
• 关键词: Antibodies; Drug Kinetics; Evaluation; Funding; Grant; Hepatitis C virus; Immune; Immunotherapy; Interleukin-10; National Center for Research Resources; Pan Genus; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Source; United States National Institutes of Health; Viremia; base; cost; humanized monoclonal antibodies

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This study was performed as a combination antibody pharmacokinetic (PK) and efficacy study to evaluate an immunotherapy based on the inhibition of IL-10 activity using a humanized monoclonal antibody. The desired effect was to increase the immune responsiveness in three chimpanzees chronically infected with HCV and observe the reduction or elimination of viremia.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 本研究作为组合抗体药代动力学（PK）和功效研究进行，以评价基于使用人源化单克隆抗体抑制IL-10活性的免疫疗法。预期的效果是增加三只慢性感染HCV的黑猩猩的免疫反应性，并观察病毒血症的减少或消除。